# Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies

> **NCT05042908** · PHASE1 · COMPLETED · sponsor: **Nanjing Leads Biolabs Co.,Ltd** · enrollment: 18 (actual)

## Conditions studied

- Advanced Malignant Tumor

## Interventions

- **DRUG:** LBL-003 Injection

## Key facts

- **NCT ID:** NCT05042908
- **Lead sponsor:** Nanjing Leads Biolabs Co.,Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-02
- **Primary completion:** 2023-04-10
- **Final completion:** 2023-04-10
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2024-05-21

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05042908

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05042908, "Evaluation of LBL-003 Phase I Study in Patients With Advanced Malignancies". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT05042908. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*